#USA #Needham #Perceptive Discovery #Astatine-211 #Atley Solutions

Perceptive Discovery Launches Astatine-211 Study Capabilities

Perceptive Discovery, a prominent player in the field of preclinical research, recently announced a significant advancement with the introduction of Astatine-211 (At-211) radiopharmaceutical development studies. This launch marks a notable milestone as it establishes the company as the first provider in the US capable of executing At-211 studies, a critical step for the development of next-generation targeting therapies in both the US and UK markets.

The strategic implementation of this capability stems from a collaborative effort with Atley Solutions, a company recognized for its expertise in radiopharmaceuticals. Their collaboration aims to eliminate barriers and enhance accessibility to specialized infrastructure and scientific acumen for biotech firms looking to explore targeted alpha therapies.

At the heart of this initiative is the new setup at Perceptive Discovery’s laboratory located at Queen Mary University of London (QMUL). Here, the first Atley C100 module has been successfully installed and utilized for the purification of At-211, which is derived from an irradiated bismuth-209 target. With this innovative infrastructure now operational, Perceptive Discovery is poised to immediately assist studies in the US, backed by a reliable supply of At-211 sourced from multiple providers. Additionally, a second Atley C100 module is set to be installed at their Needham, Massachusetts facility in the near future, further extending their development capabilities for At-211.

This latest expansion allows sponsors and research organizations to tap into Perceptive Discovery's extensive resources that encompass not just At-211 radiochemistry but a broader array of preclinical and translational approaches to radiopharmaceutical development. The offerings include:

• - Internal radiolabeling expertise across diverse compounds like proteins, peptides, and small molecules.
• - A variety of precursor chemistries, showcasing versatility with boronic acids, tributyl tin, and more.
• - Advanced analytical techniques such as radio-iTLC and HPLC.
• - Comprehensive infrastructure tailored for At-211 development, bolstered by the collaboration with Atley Solutions and the operational capability at QMUL.

Ben Murphy, the CEO of Perceptive Discovery, commented on the crucial expansion this represents for their service offerings, stating, "The ability to execute At-211 studies across our UK and US operations represents an important expansion of what we can offer sponsors developing targeted alpha therapies. By combining access to At-211 with our established expertise in various domains, we empower our clients to obtain the critical data required for advancing their promising therapeutic programs toward clinical use."

The Atley C100 serves as an automated manufacturing platform specifically designed for the production of At-211 radiopharmaceuticals. The successful launch of this technology at QMUL lays a necessary groundwork for an increasing number of biotech and pharmaceutical companies eager to explore the benefits of At-211-based treatments.

Milton Lönnroth, CEO of Atley Solutions, echoed the sentiment on the significance of this collaboration, emphasizing its role in providing necessary infrastructure in both the US and UK. This commitment aims to catalyze advancements in the development of At-211 radiopharmaceuticals, ensuring that developers have the resources they need to succeed.

With these developments in place, Perceptive Discovery is now welcoming inquiries for Astatine-211 development programs at its facilities, expanding its role as a key partner in the ongoing evolution of radiopharmaceutical innovation.

About Atley Solutions

Atley Solutions specializes in the development of solutions for At-211 radiopharmaceuticals, providing not only manufacturing technologies like the Atley C100 module but also comprehensive radiopharmaceutical development services.

About Perceptive Discovery

Perceptive Discovery is dedicated to enabling sponsors to produce vital evidence that advances promising therapeutics through research in radiochemistry, imaging, oncology, and more, guiding products from discovery through to clinical application.